Results 1 to 10 of about 385 (131)

A systematic review of present and future pharmaco‐structural therapies for hypertrophic cardiomyopathy

Clinical Cardiology, Volume 47, Issue 1, January 2024.
Hypertrophic cardiomyopathy (HCM) is an increasingly recognized genetic condition that is accompanied by a heterogeneous phenotype. The presence of outflow tract obstruction carries an increased risk for the development of heart failure, arrhythmias, and sudden cardiac death.
Mariem A. Sawan, Sindhu Prabakaran, Melroy D'Souza, Omid Behbahani‐Nejad, Matthew E. Gold, Byron Robinson Williams, Ozlem Bilen   +6 more
wiley   +1 more source

How effective is disopyramide in treating pediatric hypertrophic cardiomyopathy? State of the art and future directions

Monaldi Archives for Chest Disease
Pediatric hypertrophic cardiomyopathy (HCM) has a wide range of clinical manifestations. Left ventricular outflow tract obstruction (LVOTO) at rest is present in up to one-third of children with HCM, with a further 50-60% of symptomatic children ...
Karin Del Vecchio, Caterina Rizzardi, Alice Pozza, Francesco Prati, Luisa Ye, Alessia Fattoretto, Elena Reffo, Giovanni Di Salvo   +7 more
doaj   +1 more source

Obstructive hypertrophic cardiomyopathy: from genetic insights to a multimodal therapeutic approach with mavacamten, aficamten, and beyond

The Egyptian Heart Journal
Background A cardiac condition marked by excessive growth of heart muscle cells, hypertrophic cardiomyopathy (HCM) is a complex genetic disorder characterized by left ventricular hypertrophy, microvascular ischemia, myocardial fibrosis, and diastolic ...
Khadija Sarwer, Saeeda Lashari, Nida Rafaqat, Maher, Abdul Raheem, Muneeb Ur Rehman, Syed Muhammad Iraj Abbas   +6 more
doaj   +1 more source

Cardiac Myosin Inhibitors as a Novel Treatment Option for Obstructive Hypertrophic Cardiomyopathy: Addressing the Core of the Matter

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022
Ahmad Masri, Iacopo Olivotto
doaj   +1 more source

Efficacy of cardiac myosin inhibitors mavacamten and aficamten in hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomised controlled trials

Open Heart
Background Unlike other suggested therapies, myosin inhibitors have been shown to change the course of hypertrophic cardiomyopathy by altering the contractile mechanics of cardiomyocytes.
Ayesha Aman, Arfa Akram, Bisma Akram, Momina Maham, Masooma Zainab Bokhari, Aleena Akram, Sania Akram, Furqan Yaqub   +7 more
doaj   +1 more source

Hypertrophic Cardiomyopathy in the Era of Targeted Therapy: The Role of Cardiac Myosin Inhibitors, Contemporary Sudden Cardiac Death Risk Stratification, and the Importance of Differential Diagnosis — A Narrative Review

Journal of Education, Health and Sport
Introduction and purpose: Hypertrophic cardiomyopathy (HCM) is a common genetic myocardial disease characterized by unexplained left ventricular hypertrophy, phenotypic heterogeneity, and a clinical course ranging from asymptomatic presentation to heart
Julia Parda, Jakub Bundyra, Dominika Janik, Oliwia Zuzanna Gańska, Agata Sochocka, Zuzanna Zapart, Martyna Szepietowska, Nina Nowicka, Alicja Sikorska, Emil Mian   +9 more
doaj   +1 more source

Issue Information

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 12, Page 1893-1896, December 2025.
wiley   +1 more source

Integrative Approaches in the Management of Hypertrophic Cardiomyopathy: A Comprehensive Review of Current Therapeutic Modalities

Biomedicines
Hypertrophic cardiomyopathy (HCM) is often associated with left ventricular outflow tract (LVOT) obstruction, which affects a substantial proportion of patients.
Marco Maria Dicorato, Gaetano Citarelli, Francesco Mangini, Rossella Alemanni, Miriam Albanese, Sebastiano Cicco, Cosimo Angelo Greco, Cinzia Forleo, Paolo Basile, Maria Cristina Carella, Marco Matteo Ciccone, Andrea Igoren Guaricci, Ilaria Dentamaro   +12 more
doaj   +1 more source

Hypertrophic cardiomyopathy: insights into pathophysiology and novel therapeutic strategies from clinical studies

The Egyptian Heart Journal
Background Hypertrophic cardiomyopathy (HCM) is a frequently encountered cardiac condition worldwide, often inherited, and characterized by intricate phenotypic and genetic manifestations.
Samuel Oluwadare Olalekan, Olalekan Olanrewaju Bakare, Patrick Godwin Okwute, Ifabunmi Oduyemi Osonuga, Muinat Moronke Adeyanju, Victoria Biola Edema   +5 more
doaj   +1 more source

Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term study. [PDF]

Eur Heart J
Tower-Rader A, Masri A, Nassif ME, Abraham TP, Barriales-Villa R, Choudhury L, Cooper RM, Elliott PM, Maron MS, Olivotto I, Oreziak A, Owens AT, Solomon SD, Heitner SB, Jacoby DL, Kupfer S, Liu X, Malik FI, Melloni C, Simkins TJ, Wei J, Saberi S.   +21 more
europepmc   +1 more source